Journal of Japanese Society of Wound, Ostomy and Continence Management
Online ISSN : 1884-2321
Print ISSN : 1884-233X
Volume 26, Issue 4
Displaying 1-12 of 12 articles from this issue
Original Article
  • Nagisa Fujii, Yoshie Ichikawa
    Article type: Original Article
    2023Volume 26Issue 4 Pages 316-324
    Published: 2023
    Released on J-STAGE: January 26, 2023
    JOURNAL FREE ACCESS
     Background: Zinc oxide ointment may be difficult to use on loose or wrinkled skin in patients with incontinence-associated dermatitis (IAD). A skin protectant featuring polymer-cyanoacrylate technology that coats erosions has been used for IAD and is expected to be useful for loose or wrinkled skin as well.
     Objective: To compare the efficacy of zinc oxide ointment and the cyanoacrylate-blended coating agent in elderly dialysis patients with severe IAD.
     Method: The present, retrospective, cohort study included nine patients receiving zinc oxide ointment and 12 patients receiving the coating agent. The IAD-set scores were evaluated weekly for up to 49 days.
     Results: The IAD-set score was 11.0 (9-18)in the ointment group and 11.0 (5-18)in the coating agent group on day 0 of the intervention(p = 0.808). On day 7, the score was 11.0 (6-17)and 6.0 (0-16)(p = 0.031), and on day 14, it was 10.5 (6-19)and 5.0 (0-14)(p = 0.034)for the respective group.
     Changes in the unhealed rate suggested that the cyanoacrylate-blended coating agent was significantly more effective (p = 0.004).
     Discussion: Friction removed the zinc oxide ointment from the skin, rendering it ineffective in treating IAD. However, the coating agent adhered to loose and wrinkled skin, including the areas affected by erosion, and was able to protect it from irritants.
     Conclusion: The present study revealed that the cyanoacrylate-blended skin protectant was effective for treating severe IAD.
    Download PDF (942K)
  • Yuko Imakata, Nao Miyamae, Junko Sugama, Makoto Oe
    Article type: Original Article
    2023Volume 26Issue 4 Pages 325-334
    Published: 2023
    Released on J-STAGE: January 26, 2023
    JOURNAL FREE ACCESS
    Background
     Docetaxel is a key anticancer drug for the treatment of breast cancer. Edema is a known side effect of treatment. In patients with breast cancer, the treatment of edema focuses on that of lymphedema. To establish treatment for the edemas caused by docetaxel therapy in breast cancer patients, this study aimed to summarize the evidence on the clinical features of such edemas.
    Methods
     A scoping review design was used. We limited our search to articles titles published in English. We included studies involving participants of all ages and at all stages of breast cancer. We searched the PubMed, CINAHL, and Cochrane Central databases for articles published between January 2006 and July 2021.
    Results
     A total of 283 articles were found, and eight papers were deemed eligible for inclusion. The site of edema formation was mainly the upper and lower limbs. Edema appeared three weeks after the end of the docetaxel regimen, and edema in the legs and arm on the contralateral side of the surgery returned to the pre-docetaxel level after 6 months of chemotherapy.
    Conclusion
     It was difficult to distinguish edema of the upper limbs due to docetaxel in patients with breast cancer from lymphedema due to lymph node dissection. In order to establish management strategies of docetaxel-related edema, it is necessary to characterize lower-limb edema, which are not affected by lymph node dissection.
    Download PDF (624K)
  • Supriadi Syafiie Saad, Suriadi, Mayumi Okuwa, Hiromi Sanada, Junko Su ...
    Article type: Original Article
    2023Volume 26Issue 4 Pages 335-346
    Published: 2023
    Released on J-STAGE: January 26, 2023
    JOURNAL FREE ACCESS
     Discontinuation of treatment of diabetic foot ulcers may impair wound healing. However, the factors related to discontinuation of wound clinic visits by patients with diabetic foot ulcers are unclear. Thus, measures for the prevention of treatment discontinuation remain to be elucidated. This prospective study aimed to investigate time required for healing, cost, and quality of life when the treatment was continued until recovery, and to clarify factors associated with the discontinuation of clinic visits. A total of 73 participants with diabetic foot ulcers were enrolled, including 15 participants with healed ulcers and 58 participants who discontinued wound care specialist clinic visits. The cumulative clinic visit discontinuation rate at 10 days was 51%. The average wound healing time was 31.5±21.0 days and the total cost was $150.20±118.84. The average utility score and visual analog scale score for perception of overall health at baseline were 0.55±0.20 and 69.67±11.87, and at recovery were 0.91±0.16 and 93.00±5.92, respectively. The factors associated with clinic visit discontinuation were low monthly income(hazard ratio: 1.87, 95% confidence interval[CI]: 1.02-3.43, p = 0.044)and lower satisfaction with access to health services(hazard ratio: 5.06, 95% CI: 2.34-10.97, p < 0.001). The introduction of an insurance system to subsidize at least 69.7% of diabetic foot ulcer treatment costs is necessary, and treatment of diabetic foot ulcers by encouraging continuation of clinic visits will help improve patients’ quality of life.
    Download PDF (753K)
Short Report
Case Report
Report
feedback
Top